Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
about
Therapeutic options for management of endometrial hyperplasiaNew concepts for an old problem: the diagnosis of endometrial hyperplasiaMolecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devicesMechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.Endometrial carcinoma in high-risk populations: is it time to consider a screening policy?
P2860
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
@ast
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
@en
type
label
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
@ast
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
@en
prefLabel
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
@ast
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
@en
P2093
P2860
P1476
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression
@en
P2093
Carolyn D Jordan
Elizabeth M Swisher
Jennifer A Doherty
Katherine M Newton
Kimberly H Allison
Rochelle L Garcia
Susan D Reed
P2860
P304
P356
10.1016/J.AJOG.2012.05.012
P407
P577
2012-05-16T00:00:00Z